ロード中...
Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
BACKGROUND: Radioligand therapy with [(177)Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [(177)Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval...
保存先:
| 出版年: | Eur J Nucl Med Mol Imaging |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Berlin Heidelberg
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7338828/ https://ncbi.nlm.nih.gov/pubmed/32062682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04703-3 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|